Julio Rosenstock Selected Research

Insulin Glargine (Lantus)

1/2022	Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.
1/2022	Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
6/2021	Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.
1/2021	A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.
1/2021	Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.
1/2021	Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.
1/2021	Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study.
11/2020	Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
10/2020	Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
1/2020	Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Julio Rosenstock Research Topics

Disease

185	Type 2 Diabetes Mellitus (MODY) 01/2022 - 04/2002
56	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 11/2003
50	Body Weight (Weight, Body) 11/2022 - 02/2006
33	Weight Loss (Weight Reduction) 11/2022 - 05/2005
23	Weight Gain 06/2021 - 06/2004
18	Nausea 10/2021 - 02/2006
15	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 01/2005
14	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 07/2015
12	Overweight 11/2022 - 11/2003
12	Vomiting 10/2021 - 01/2011
12	Infections 01/2019 - 06/2012
11	Heart Failure 08/2022 - 07/2012
9	Obesity 11/2022 - 03/2005
8	Kidney Diseases (Kidney Disease) 01/2022 - 09/2015
8	Myocardial Infarction 10/2021 - 11/2016
8	Stroke (Strokes) 10/2021 - 11/2016
8	Hyperglycemia 01/2018 - 07/2010
7	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2022 - 03/2015
6	Pancreatitis 10/2021 - 01/2017
5	Prediabetic State (Prediabetes) 08/2022 - 07/2010
5	Insulin Resistance 01/2021 - 10/2006
5	Diarrhea 01/2021 - 01/2011
5	Albuminuria 04/2020 - 09/2015
5	Urinary Tract Infections (Urinary Tract Infection) 01/2018 - 06/2012
4	Chronic Renal Insufficiency 12/2021 - 01/2019
4	Body Weight Changes 06/2021 - 02/2006
4	Injection Site Reaction 11/2020 - 03/2013
4	Diabetes Mellitus 01/2020 - 05/2002
4	Edema (Dropsy) 07/2012 - 03/2006
3	Pain (Aches) 11/2017 - 08/2004
3	Neuralgia (Stump Neuralgia) 11/2017 - 09/2008
3	Dizziness (Lightheadedness) 12/2014 - 08/2004
3	Peripheral Nervous System Diseases (PNS Diseases) 02/2013 - 08/2004
2	Proteinuria 09/2021 - 01/2021
2	Constipation 01/2021 - 01/2011
2	Cognitive Dysfunction 11/2020 - 10/2019
2	Hypersensitivity (Allergy) 11/2020 - 03/2013

Drug/Important Bio-Agent (IBA)

75	Insulin (Novolin)FDA Link 01/2022 - 04/2002
61	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 11/2003
57	Metformin (Glucophage)FDA LinkGeneric 11/2020 - 05/2005
48	Insulin Glargine (Lantus)FDA Link 01/2022 - 11/2003
23	Glucagon-Like Peptide-1 ReceptorIBA 01/2022 - 10/2009
19	lixisenatideIBA 01/2022 - 09/2013
19	LinagliptinIBA 09/2021 - 08/2012
18	Exenatide (Byetta)FDA Link 10/2021 - 05/2005
18	Hypoglycemic Agents (Hypoglycemics)IBA 06/2021 - 10/2004
17	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021 - 09/2002
16	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 07/2009
14	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 07/2012
14	Sodium-Glucose Transport ProteinsIBA 01/2021 - 06/2012
14	Pharmaceutical PreparationsIBA 01/2019 - 02/2006
13	semaglutideIBA 11/2022 - 11/2016
12	Liraglutide FDA Link 11/2022 - 07/2009
11	empagliflozinIBA 08/2022 - 07/2014
11	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 04/2014
11	LipidsIBA 03/2012 - 03/2005
9	CreatinineIBA 01/2022 - 06/2012
8	omega-Chloroacetophenone (Mace)IBA 10/2021 - 01/2019
8	glimepiride (Amarel)FDA LinkGeneric 01/2021 - 08/2012
8	dapagliflozinIBA 01/2020 - 07/2012
7	InsulinsIBA 01/2022 - 04/2012
7	AlbuminsIBA 01/2022 - 09/2015
7	SodiumIBA 01/2022 - 07/2012
7	Blood Glucose (Blood Sugar)IBA 01/2021 - 03/2010
7	Dipeptidyl-Peptidase IV InhibitorsIBA 11/2020 - 01/2008
7	Pioglitazone (Actos)FDA Link 11/2019 - 10/2006
7	saxagliptin FDA Link 01/2019 - 11/2010
6	LDL CholesterolIBA 01/2022 - 08/2008
6	(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA 12/2021 - 07/2013
6	rGLP-1 proteinIBA 11/2021 - 10/2009
6	insulin degludecIBA 01/2021 - 03/2011
6	CanagliflozinIBA 01/2019 - 06/2012
6	Colesevelam Hydrochloride (Welchol)FDA Link 07/2012 - 08/2008
5	efpeglenatideIBA 01/2022 - 01/2019
5	Sitagliptin Phosphate (Januvia)FDA Link 01/2019 - 10/2006
5	2,4-thiazolidinedione (thiazolidinedione)IBA 01/2018 - 09/2002
4	Protamines (Protamine Sulfate)FDA Link 06/2021 - 10/2004
4	IncretinsIBA 01/2021 - 05/2005
4	Hemoglobins (Hemoglobin)IBA 01/2019 - 07/2010
4	LY2605541IBA 01/2014 - 11/2012
4	Exubera FDA Link 03/2010 - 06/2004
4	PowdersIBA 03/2010 - 02/2007
3	Insulin Aspart (NovoLog)FDA Link 06/2021 - 10/2004
3	insulin aspart protamine drug combination 30:70 insulin aspartIBA 06/2021 - 10/2004
3	SuspensionsIBA 10/2020 - 01/2008
3	Insulin Lispro (Humalog)FDA Link 10/2020 - 01/2008
3	insulin glulisine FDA Link 08/2016 - 10/2004
3	Short-Acting InsulinIBA 01/2016 - 09/2013
3	Isophane Insulin (NPH Insulin)FDA Link 11/2012 - 11/2004
3	oxidized low density lipoproteinIBA 07/2012 - 07/2010
3	VildagliptinIBA 01/2008 - 02/2007
2	KetonesIBA 01/2022 - 12/2018
2	tirzepatideIBA 10/2021 - 01/2021
2	Peptides (Polypeptides)IBA 10/2021 - 01/2021
2	insulin icodecIBA 01/2021 - 11/2020

Therapy/Procedure

71	Therapeutics 08/2022 - 09/2002
58	Glycemic Control 01/2022 - 04/2002
15	Injections 01/2022 - 04/2002
4	Subcutaneous Injections 01/2021 - 04/2002
2	Aftercare (After-Treatment) 01/2022 - 12/2011